Circulating microRNAs as stable blood-based markers for cancer detection

  title={Circulating microRNAs as stable blood-based markers for cancer detection},
  author={Patrick S. Mitchell and Rachael K. Parkin and Evan M. Kroh and Brian R. Fritz and Stacia K. Wyman and Era L. Pogosova-Agadjanyan and Amelia C. Peterson and Jennifer Noteboom and K C O'briant and April N Allen and Daniel W. Lin and Nicole D. Urban and Charles W. Drescher and Beatrice S. Knudsen and Derek L. Stirewalt and Robert Gentleman and Robert L. Vessella and Peter S. Nelson and Daniel B. Martin and Muneesh Tewari},
  journal={Proceedings of the National Academy of Sciences},
  pages={10513 - 10518}
Improved approaches for the detection of common epithelial malignancies are urgently needed to reduce the worldwide morbidity and mortality caused by cancer. MicroRNAs (miRNAs) are small (≈22 nt) regulatory RNAs that are frequently dysregulated in cancer and have shown promise as tissue-based markers for cancer classification and prognostication. We show here that miRNAs are present in human plasma in a remarkably stable form that is protected from endogenous RNase activity. miRNAs originating… 

Figures from this paper

Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers
Newly uncovered cellular and molecular mechanisms of the sources and stability of circulating miRNAs are presented, revealing their great potential as a class of highly specific and sensitive biomarkers for tumor classification and prognostication.
Circulating miRNAs as new blood-based biomarkers for solid cancers.
The origin of circulating miRNAs, principles of their immense stability and proposed functions, and comprehensively summarize studies focusing on their significance in the most frequently studied cancer types in this regard are described.
Circulating microRNAs: macro-utility as markers of prostate cancer?
The potential of blood-based circulating miRNAs as diagnostic, prognostic, and predictive biomarkers of prostate cancer and evidence is prevented for the emerging concept that circulating mi RNAs are actively released by their cells of origin and can modulate gene expression at distal sites.
Assessment of Circulating microRNAs in Plasma of Lung Cancer Patients
By monitoring changes of plasma miRNA-ratios, it is possible to assess the deregulation of tumor-related miRNAs and identify signatures with diagnostic and prognostic value and could be potentially applied for the identification of diagnostic circulating miRNAAs in other diseases.
Circulating MicroRNA as Biomarkers: An Update in Prostate Cancer.
Prostate cancer (PCa) is the most common non-skin cancer among men. Currently available diagnostic tests for PCa are inadequate in terms of low specificity and poor sensitivity. microRNAs offer a
MicroRNAs as Blood-based Biomarkers of Cancer
This chapter is to review the recently reported studies on the circulating miRNAs in cancer patients and to estimate their great potential as a class of highly specific and sensitive blood-based biomarkers for tumor classification and prognostication.
Circulating Plasma MicroRNAs As Diagnostic Markers for NSCLC
Insight is provided into the miRNAs biology, the mechanisms of miRNA-panels release into the bloodstream, cell-free miRNAAs as the diagnostic markers for NSCLC and the current limitations of CTCs as diagnostic markers inNSCLC.
Circulating cell-free microRNAs as clinical cancer biomarkers
The origins and roles of miRNAs are described, and the most recent studies focusing on their usefulness as cancer biomarkers in lung, breast, colon, prostate, ovary cancers and melanoma are summarized.
Circulating MicroRNAs in blood of patients with prostate cancer.
Circulating miRNAs in cancer: from detection to therapy
The progresses made over the past decade regarding circulating miRNAs are summarized, from the development of detection methods to their clinical application as biomarkers and therapeutic tools for cancer, and their clinical pharmacokinetics and toxicity in human organs are highlighted.


Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma
This is the first description of circulating microRNAs and suggests that micro RNAs have potential as non‐invasive diagnostic markers for DLBCL and possibly other cancers.
MicroRNA expression profiling in prostate cancer.
Hierarchical clustering of the tumor samples by their miRNA expression accurately separated the carcinomas from the BPH samples and also further classified the carcinoma tumors according to their androgen dependence, indicating the potential of miRNAs as a novel diagnostic and prognostic tool for prostate cancer.
Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics.
The data suggest that measurement of circulating RNA may not be a good approach to early cancer diagnosis, and extracellular RNA is most likely protected within protein or lipid vesicles, possibly apoptotic bodies, which can be disrupted by detergents.
MicroRNA expression profiles classify human cancers
A new, bead-based flow cytometric miRNA expression profiling method is used to present a systematic expression analysis of 217 mammalian miRNAs from 334 samples, including multiple human cancers, and finds the miRNA profiles are surprisingly informative, reflecting the developmental lineage and differentiation state of the tumours.
Detection and characterization of placental microRNAs in maternal plasma.
The existence of placental miRNAs in maternal plasma is demonstrated and some information on their stability and physical nature is provided to open up a new class of molecular markers for pregnancy monitoring.
MicroRNA signatures in human cancers
MiRNA-expression profiling of human tumours has identified signatures associated with diagnosis, staging, progression, prognosis and response to treatment and has been exploited to identify miRNA genes that might represent downstream targets of activated oncogenic pathways, or that target protein-coding genes involved in cancer.
Oncomirs — microRNAs with a role in cancer
Evidence has shown that miRNA mutations or mis-expression correlate with various human cancers and indicates that miRNAs can function as tumour suppressors and oncogenes.
RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain.
The ability to profile miRNAs from archival tissues at the tissue level, by RAKE microarrays, and at the cellular level by LNA-ISH, will accelerate studies of miRNAAs in human diseases.
Circulating nucleic acids in plasma/serum
Studies of circulating nucleic acids have promised exciting developments in molecular diagnostics in the years to come and pre‐analytical standardisation will become increasingly relevant when comparing data from different laboratories.
Real-time quantification of microRNAs by stem–loop RT–PCR
A novel microRNA quantification method has been developed using stem–loop RT followed by TaqMan PCR analysis, which enables fast, accurate and sensitive miRNA expression profiling and can identify and monitor potential biomarkers specific to tissues or diseases.